myo-Inositol trispyrophosphate (hexasodium)
CAT:
804-HY-141510-05
Size:
50 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
myo-Inositol trispyrophosphate (hexasodium)
- CAS Number: 23103-35-7
- UNSPSC Description: myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer[1][2][3].
- Target Antigen: HIF/HIF Prolyl-Hydroxylase
- Type: Reference compound
- Related Pathways: Metabolic Enzyme/Protease
- Applications: Cancer-programmed cell death
- Field of Research: Cancer; Cardiovascular Disease
- Assay Protocol: https://www.medchemexpress.com/myo-inositol-trispyrophosphate-hexasodium.html
- Solubility: H2O : 25 mg/mL (ultrasonic)
- Smiles: O=P1(O[C@]2([H])[C@@]3([H])[C@@](OP(OP(O3)(O[Na])=O)(O[Na])=O)([H])[C@]4([H])[C@@](OP(OP(O4)(O[Na])=O)(O[Na])=O)([H])[C@@]2([H])OP(O1)(O[Na])=O)O[Na]
- Molecular Weight: 737.88
- References & Citations: [1]Raykov Z, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82.|[2]Fylaktakidou KC, et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8.|[3]Oknińska M, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283.
- Shipping Conditions: Blue Ice
- Clinical Information: No Development Reported